
Sai Life Sciences, Agility Life Sciences, And Centrix Pharma Solutions Announce An 'Integrated CMC Partnership' To Accelerate Drug Development For Innovators
Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond.
Unified expertise, seamless execution
By combining deep expertise across the CMC value chain, the Integrated CMC Partnership helps customers create and execute holistic development plans-translating molecular hits into new medicines. Key benefits include:
- Broad scientific expertise across multiple disciplines, supported by extensive laboratory and manufacturing facilities End-to-end service coverage from synthetic route scouting to drug substance manufacturing, and from pre-formulation through to clinical trial material manufacturing Cross-functional optimization : integrated planning across API and drug product development, reducing duplication, risks, costs, and timelines Agility and flexibility to respond proactively to emerging technical risks across functions Seamless coordination between technical teams, including proactive sample transfer and early API evaluation in the drug product process Single point of contact from Day One, ensuring alignment and accountability throughout project execution
The result is a faster, more efficient, and more collaborative pathway for innovators to advance their drug candidates with confidence.
Quotes from the partners
"We are delighted to partner with Agility Life Sciences and Centrix Pharma in this truly integrated CMC offering. By bringing together our complementary strengths, we can deliver far greater value to innovators-helping them translate ideas into medicines with speed, quality, and efficiency. This partnership reflects our shared commitment to supporting customers on their journey from discovery to the clinic, and ultimately, to patients.” - Krishna Kanumuri, MD & CEO, Sai Life Sciences
“We are delighted to be entering this partnership with Sai and Centrix. Our combined expertise and energy will enable our clients' molecules to be accelerated through key milestones, while reducing risk and cost.” - Dr Claire Thompson, CEO and Founder, Agility Life Sciences .
“What excites me most about this partnership is the spirit of collaboration it represents. By bringing together talented teams across Sai, Agility, and Centrix, we are creating a seamless environment where expertise flows freely, challenges are solved collectively, and clients benefit from true alignment. At its heart, this is about people working side by side to turn promising science into medicines that can change lives.” - Chris Davison, CEO, Centrix Pharma Solutions.
About Sai Life Sciences
Sai Life Sciences is a leading integrated Contract Research, Development & Manufacturing Organization (CRDMO) working with over 300 innovator pharma and biotech companies globally to accelerate the discovery, development, and manufacture of complex small molecules. With over 3,400 employees, state-of-the-art facilities in India, UK, and USA, and a strong focus on sustainability, Sai enables customers to bring new medicines to patients faster. | ...
About Agility Life Sciences
Agility Life Sciences is an award-winning formulation development CDMO helping pharmaceutical and biotech companies overcome bioavailability, stability, and delivery challenges. Known for its problem-solving expertise and flexible approach, Agility's“Fast Futureproof Formulations” approach creates tailored formulations that enable molecules to progress rapidly into and through the clinic. | ...
About Centrix Pharma Solutions
Centrix Pharma Solutions is a specialist CDMO focused on drug product development and clinical trial manufacturing. Building on decades of expertise, we provide science-driven, patient-centric solutions that accelerate the journey from molecule to medicine, combining technical depth, flexible execution, and a commitment to quality that delivers value for partners and patients alike. | ...
CONTACT: For further information, contact: Sriram Gopalakrishnan Vice President, Corporate Communication Sai Life Sciences Limited Ph: +91 9121295355 ...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Pepeto Presale Exceeds $6.93 Million Staking And Exchange Demo Released
- Citadel Launches Suiball, The First Sui-Native Hardware Wallet
- Luminadata Unveils GAAP & SOX-Trained AI Agents Achieving 99.8% Reconciliation Accuracy
- Tradesta Becomes The First Perpetuals Exchange To Launch Equities On Avalanche
- Thinkmarkets Adds Synthetic Indices To Its Product Offering
- Edgen Launches Multi‐Agent Intelligence Upgrade To Unify Crypto And Equity Analysis
Comments
No comment